Compare CFG & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFG | INSM |
|---|---|---|
| Founded | 1828 | 1988 |
| Country | United States | United States |
| Employees | 17398 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7B | 23.0B |
| IPO Year | N/A | 2000 |
| Metric | CFG | INSM |
|---|---|---|
| Price | $61.59 | $102.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 24 |
| Target Price | $70.17 | ★ $201.17 |
| AVG Volume (30 Days) | 3.6M | ★ 4.2M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.17 | $182.31 |
| Revenue Next Year | $8.30 | $65.19 |
| P/E Ratio | $16.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.70 | $70.57 |
| 52 Week High | $68.79 | $212.75 |
| Indicator | CFG | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 33.07 |
| Support Level | $58.09 | $98.90 |
| Resistance Level | $62.16 | $166.81 |
| Average True Range (ATR) | 1.30 | 4.03 |
| MACD | -0.10 | 0.66 |
| Stochastic Oscillator | 39.14 | 13.66 |
Citizens Financial Group Inc is a bank holding company headquartered in Providence, Rhode Island. Through its subsidiaries, it offers various retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations, and institutions. The group's reportable business segments are: Consumer Banking and Commercial Banking. The majority of its revenue is generated from the Consumer Banking segment, which serves consumer customers and small businesses, offering traditional banking products and services, including deposits, mortgage and home equity lending, credit cards, small business loans, education loans, point-of-sale finance loans, and wealth management solutions, among others, through a network of branches and ATMs.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.